Status:

COMPLETED

The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

Lead Sponsor:

Tanabe Pharma Corporation

Conditions:

Perennial Allergic Rhinitis

Eligibility:

All Genders

7-15 years

Phase:

PHASE3

Brief Summary

The objectives of this study are: to confirm the superiority of TAU-284 over placebo after two weeks of administration to pediatric patients with perennial allergic rhinitis and to investigate safety ...

Detailed Description

This is a randomized, double-blind, placebo-controlled, 2-arm parallel-group comparative study to confirm the superiority of TAU-284 over placebo after two weeks of administration of TAU-284 (20 mg/da...

Eligibility Criteria

Inclusion

  • Patients aged between 7 and 15 years
  • Patients who have received a diagnosis of perennial allergic rhinitis according to the diagnostic criteria
  • Patients with a mean rhinorrhea score and a mean sneezing score of at least 2 on the basis of symptoms recorded in the nasal allergy diary during the observation period etc.

Exclusion

  • Patients with vasomotor rhinitis or eosinophilic rhinitis
  • Patients who have concurrent nasal disease that may affect the efficacy of TAU-284
  • Patients with a history of any of the nasal surgical procedures
  • Patients who have a positive result for pollen antigens which are dispersed during the study period
  • Patients who have a positive result for dog dander or cat dander antigen and have a chance to touch dogs or cats.
  • Patients with current or previous history of drug allergy
  • Patients who concurrently have renal function abnormalities that may cause safety problems etc.

Key Trial Info

Start Date :

April 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2013

Estimated Enrollment :

473 Patients enrolled

Trial Details

Trial ID

NCT01861522

Start Date

April 1 2013

End Date

December 1 2013

Last Update

January 8 2026

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Reserch site

Fukuoka, Japan

2

Reserch site

Toyama, Japan